Drugs /

lenvatinib

Back to Drugs List
Associated Genetic Biomarkers
Associated Diseases

Overview

Generic Name(s):
lenvatinib
Trade Name(s):
Lenvima
NCI Definition [1]:
A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. Lenvatinib blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis.

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for lenvatinib

Lenvatinib has been investigated in 74 clinical trials, of which 71 are open and 3 are closed. Of the trials investigating lenvatinib, 8 are phase 1 (8 open), 10 are phase 1/phase 2 (10 open), 38 are phase 2 (35 open), 16 are phase 3 (16 open), and 2 are no phase specified (2 open).

EGFR A763_Y764insFQEA, EGFR Exon 19 Deletion, and EGFR Exon 19 Insertion are the most frequent biomarker inclusion criteria for lenvatinib clinical trials.

Clear cell renal cell carcinoma, hepatocellular carcinoma, and melanoma are the most common diseases being investigated in lenvatinib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Lenvatinib
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Lenvatinib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating lenvatinib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
e7080, Lenvima, multi-kinase inhibitor e7080, 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide, 4-(3-chloro-4-((cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide, lenvatinib, 4-(3-chloro-4-(n'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide, er-203492-00, lenvatinib (product), lenvatinib (substance), 6-quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]- 7-methoxy-, lenvatinib
Drug Categories [2]:
Tyrosine kinase inhibitors, VEGFR-2 inhibitors
Drug Target(s) [2]:
FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, KIT, PDGFRA, RET
NCIT ID [1]:
C95124
SNOMED ID [1]:
C-F08CE

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.